N,N-Dimethyl-2-{3-[2-methyl-4-(2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-benzyl]-ureido}-acetamide

ID: ALA182852

Chembl Id: CHEMBL182852

Cas Number: 335154-66-0

PubChem CID: 6918573

Max Phase: Preclinical

Molecular Formula: C24H30N4O3

Molecular Weight: 422.53

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cc(C(=O)N2CCCCc3ccccc32)ccc1CNC(=O)NCC(=O)N(C)C

Standard InChI:  InChI=1S/C24H30N4O3/c1-17-14-19(11-12-20(17)15-25-24(31)26-16-22(29)27(2)3)23(30)28-13-7-6-9-18-8-4-5-10-21(18)28/h4-5,8,10-12,14H,6-7,9,13,15-16H2,1-3H3,(H2,25,26,31)

Standard InChI Key:  KJEZELOIMUVVFM-UHFFFAOYSA-N

Associated Targets(Human)

AVPR2 Tclin Vasopressin V2 receptor (2912 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Avpr2 Vasopressin V2 receptor (776 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 422.53Molecular Weight (Monoisotopic): 422.2318AlogP: 2.87#Rotatable Bonds: 5
Polar Surface Area: 81.75Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: 2.32CX LogD: 2.32
Aromatic Rings: 2Heavy Atoms: 31QED Weighted: 0.78Np Likeness Score: -1.83

References

1. Pitt GR, Batt AR, Haigh RM, Penson AM, Robson PA, Rooker DP, Tartar AL, Trim JE, Yea CM, Roe MB..  (2004)  Non-peptide oxytocin agonists.,  14  (17): [PMID:15357997] [10.1016/j.bmcl.2004.04.107]
2. Yea CM, Allan CE, Ashworth DM, Barnett J, Baxter AJ, Broadbridge JD, Franklin RJ, Hampton SL, Hudson P, Horton JA, Jenkins PD, Penson AM, Pitt GR, Rivière P, Robson PA, Rooker DP, Semple G, Sheppard A, Haigh RM, Roe MB..  (2008)  New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.,  51  (24): [PMID:19053774] [10.1021/jm8008162]

Source